Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Depei Wu

Showing results (71-80 of 579) with videos related to

Pageof 58
Sort By:
Leukemia Research|May 30, 2015
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemiaLimin Liu, Qi Qu, Wenjing Jiao, et al.
Cancer Medicine|January 13, 2022
Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemiaShiyu Han, Jiaqian Qi, Kun Fang, et al.
Frontiers of Medicine|June 24, 2015
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phaseLanping Xu, Huanling Zhu, Jianda Hu, et al.
Experimental Hematology & Oncology|November 10, 2022
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHDYin Liu, Ye Zhao, Jiaqian Qi, et al.
Leukemia Research|December 15, 2010
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemiaYanhui Liu, Zhaoyue Wang, Miao Jiang, et al.
International Journal of Hematology|May 27, 2014
TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutationsXiaopeng Tian, Yang Xu, Jia Yin, et al.
Chinese Medical Journal|August 10, 2025
Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapyChengcheng Fu, Yingying Zhai, Lingzhi Yan, et al.
Annals of Hematology|February 17, 2024
Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomabShaoyu Liu, Qingya Cui, Mengyun Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 3, 2015
[Clinical and laboratory characteristics of 12 Ph/BCR-ABL positive acute myeloid leukemia patients]Wenzhi Cai, Xuefeng He, Suning Chen, et al.
Patient Related Outcome Measures|October 4, 2023
Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in ChinaShanlian Hu, Depei Wu, Jing Wu, et al.
Pageof 58

Showing results (71-80 of 579) with videos related to

Sort By:
Pageof 58
Leukemia Research|May 30, 2015
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemiaLimin Liu, Qi Qu, Wenjing Jiao, et al.
Cancer Medicine|January 13, 2022
Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemiaShiyu Han, Jiaqian Qi, Kun Fang, et al.
Frontiers of Medicine|June 24, 2015
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phaseLanping Xu, Huanling Zhu, Jianda Hu, et al.
Experimental Hematology & Oncology|November 10, 2022
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHDYin Liu, Ye Zhao, Jiaqian Qi, et al.
Leukemia Research|December 15, 2010
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemiaYanhui Liu, Zhaoyue Wang, Miao Jiang, et al.
International Journal of Hematology|May 27, 2014
TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutationsXiaopeng Tian, Yang Xu, Jia Yin, et al.
Chinese Medical Journal|August 10, 2025
Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapyChengcheng Fu, Yingying Zhai, Lingzhi Yan, et al.
Annals of Hematology|February 17, 2024
Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomabShaoyu Liu, Qingya Cui, Mengyun Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 3, 2015
[Clinical and laboratory characteristics of 12 Ph/BCR-ABL positive acute myeloid leukemia patients]Wenzhi Cai, Xuefeng He, Suning Chen, et al.
Patient Related Outcome Measures|October 4, 2023
Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in ChinaShanlian Hu, Depei Wu, Jing Wu, et al.
Pageof 58